Catatan sumber primer
PenentuHasil topline
Quince Therapeutics: Data Fase 2b PH-ILD untuk LAM-001 diperkirakan Q1 2028
Akuisisi Orphai Therapeutics menambahkan LAM-001 ke dalam pipeline Quince. Uji coba Fase 2b dengan 75 pasien pada PH-ILD sedang berlangsung dengan hasil topline yang dipandu untuk Q1 2028. Uji coba Fase 2 BOS terpisah telah terdaftar penuh dengan hasil yang diharapkan pada Q1 2027.
Fakta utama
- Diajukan
- 30 Jul 2026, 10.02
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
QNCXQuince Therapeutics, Inc.- Aset
- LAM-001
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- enrollment fase 2b
- 75 pasien
- peningkatan 6mwd fase 2a
- relevan secara klinis
- penurunan pvr fase 2a
- relevan secara klinis
- peningkatan kelas fungsional fase 2a
- Kelas III ke Kelas II
Kutipan sumber
EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann